Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...
Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...
Shu is first expert from Asia to receive the award. According to ARO, Shu was awarded for his collaborative and continued ...
Clinical Trials Arena on MSN13d
Sensorion’s Phase I/II gene therapy trial to continue with DMC recommendationSensorion's Audiogene Phase I/II trial of the SENS-501 gene therapy programme has received a favourable recommendation from ...
The preliminary results from the Audiogene study, conducted in children aged six to 31 months without cochlear hearing implants, also showed that the SENS-501 (formerly OTOF-GT) gene therapy was ...
As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing Speech and development progress followed dramatic improvements in hearing in ...
Sensorion receives DMC recommendation to continue the Audiogene phase 1/2 trial of SENS-501: Montpellier, France Monday, February 24, 2025, 18:00 Hrs [IST] Sensorion, a pioneering ...
Otoferlin-related hearing loss is an ultra-rare condition caused by mutations in the OTOF gene, leading to the absence of functional otoferlin protein essential for inner ear and auditory nerve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback